Search
The PELICAN (Prematurity’s Effects on the Lungs in Children and Adults Network) Clinical Research Collaboration was launched by the European Respiratory Society (ERS) in 2020
Cystic fibrosis is an inherited condition that results in chronic lung disease. In recent years, a new type of medication called CFTR modulators has become available.
This prospective, longitudinal cohort study will examine airway sputum, lung function, and clinical surveillance data of children with bronchiectasis attending Perth Children’s Hospital.
Senior Research Fellow
Honorary Research Associate
Co-Head, Foundations of Lung Disease
Bronchiectasis is a chronic lung disease that impairs quality of life and reduces life expectancy.
During exacerbations, when symptom and treatment burden are increased, individuals with cystic fibrosis (CF) are likely to prefer airway clearance techniques (ACTs) that require minimal effort. Therefore, in adults with CF who were hospitalised with an exacerbation, we sought to compare the effect of the MetaNeb with usual ACTs on respiratory function and expectorated sputum.
Preterm birth is associated with increased mortality and morbidity, particularly due to lung disease. Low- and middle-income countries (LMIC) have the highest rates of preterm birth. Infants born extremely preterm rarely survive, so the largest burden is amongst moderate-to-late preterm (MLP) infants. The long-term health impact on MLP children in LMIC is poorly understood. The aim of this study was to assess the effect of MLP birth on lung function trajectories from birth to 5 years in the Drakenstein Child Health Study.
Bronchiectasis (not related to cystic fibrosis) is a chronic lung disease caused by a range of etiologies but characterized by abnormal airway dilatation, recurrent respiratory symptoms, impaired quality of life and reduced life expectancy.